Evidence map›Paper›PMID 24778993›Full record

ArticleTranslational medicine @ UniSa2014

Are T-LGL Leukemia and NK-Chronic Lymphoproliferative Disorder really two distinct diseases?

Renato Zambello, Antonella Teramo, Cristina Gattazzo, Gianpietro Semenzato

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in Translational medicine @ UniSa, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04453345 (The Efficacy of Thalidomide Plus Prednisone and Methotrexate for the Symptomatic Large Granular Lymphocytic Leukemia - a Prospective Multicenter Clinical Trial From China), which is not on this map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04453345 phase2 / phase3unknown statusnot on this map

The Efficacy of Thalidomide Plus Prednisone and Methotrexate for the Symptomatic Large Granular Lymphocytic Leukemia - a Prospective Multicenter Clinical Trial From China

TypeinterventionalSponsorInstitute of Hematology & Blood Diseases Hospital, ChinaRan2013 to 2025Enrolled42ConditionsT-LGL Leukemia, Clpd-NkArmsthalidomide + prednisone + methotrexate
3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Cancers · 2020
    Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Renato ZambelloPadua University School of Medicine, Department of Medicine, Hematology and Clinical Immunology Branch , Padua, Italy ; Venetian Institute of Molecular Medicine (VIMM) , Padua, Italy.
Antonella TeramoPadua University School of Medicine, Department of Medicine, Hematology and Clinical Immunology Branch , Padua, Italy ; Venetian Institute of Molecular Medicine (VIMM) , Padua, Italy.
Cristina GattazzoPadua University School of Medicine, Department of Medicine, Hematology and Clinical Immunology Branch , Padua, Italy ; Venetian Institute of Molecular Medicine (VIMM) , Padua, Italy.
Gianpietro SemenzatoPadua University School of Medicine, Department of Medicine, Hematology and Clinical Immunology Branch , Padua, Italy ; Venetian Institute of Molecular Medicine (VIMM) , Padua, Italy.
Veneto Institute of Molecular Medicine · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mature Large Granular lymphocytes (LGL) disorders include a spectrum of conditions, ranging from polyclonal to clonal indolent and/or overt leukemic LGL proliferations. Most cases are represented by clonal expansions of TCRα/β+ LGL displaying a CD8+ phenotype with expression of cytotoxic T-cell antigens (CD57, CD16, TIA-1, perforin and granzyme B). Proliferations of CD3-CD16+ NK cells with a restricted patter of NK receptors are less common, usually comprising 15% of the cases. Main features are cytopenias, splenomegaly and autoimmune phenomena. Morphology, immunophenotyping and molecular analyses are crucial to establish a correct diagnosis of disease. According to the 2008 WHO classification, two separate entities account for the majority of cases, T-LGL leukemia and Chronic Lymphoproliferative Disease of NK cell (this latter still provisional). Although these disorders are characterized by the expansion of different cells types i.e. T and NK cells, with specific genetic features and abnormalities, compelling evidence supports the hypothesis that a common pathogenic mechanism would be involved in both disorders. As a matter of fact, a foreign antigen driven clonal selection is considered the initial step in the mechanism ultimately leading to generation of both conditions. In this chapter we will discuss recent advances on the pathogenesis of chronic T and NK disorders of granular lymphocytes, challenging the current WHO classification on the opportunity to separate T and NK disorders, which are likely to represent two sides of the same coin.

Indexed as

CLPD-NKCTLNK cellsT-LGL leukemia

Identifiers

PMID24778993
PMCPMC4000458
OpenAlexW2156739326

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.